208,510 Shares in AbbVie Inc. $ABBV Purchased by Rakuten Investment Management Inc.

Rakuten Investment Management Inc. purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 208,510 shares of the company’s stock, valued at approximately $46,531,000.

A number of other institutional investors and hedge funds also recently modified their holdings of ABBV. BankPlus Wealth Management LLC increased its position in AbbVie by 3.4% during the third quarter. BankPlus Wealth Management LLC now owns 4,347 shares of the company’s stock worth $1,007,000 after purchasing an additional 144 shares during the last quarter. Cornerstone Wealth Group LLC raised its position in shares of AbbVie by 0.4% in the 3rd quarter. Cornerstone Wealth Group LLC now owns 67,582 shares of the company’s stock worth $15,648,000 after buying an additional 278 shares during the period. Samalin Investment Counsel LLC boosted its holdings in AbbVie by 1.9% in the third quarter. Samalin Investment Counsel LLC now owns 3,390 shares of the company’s stock valued at $785,000 after acquiring an additional 64 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in AbbVie by 96.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 256,599 shares of the company’s stock valued at $59,413,000 after acquiring an additional 126,024 shares during the last quarter. Finally, Forvis Mazars Wealth Advisors LLC grew its position in AbbVie by 6.3% during the third quarter. Forvis Mazars Wealth Advisors LLC now owns 26,264 shares of the company’s stock valued at $6,081,000 after acquiring an additional 1,547 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.2%

NYSE ABBV opened at $213.90 on Wednesday. The stock has a market cap of $378.04 billion, a P/E ratio of 162.05, a PEG ratio of 0.88 and a beta of 0.36. The company’s fifty day simple moving average is $226.50 and its 200-day simple moving average is $216.99. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The company had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same period in the prior year, the company posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, research analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a yield of 3.2%. This is a boost from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio (DPR) is presently 524.24%.

Analyst Upgrades and Downgrades

ABBV has been the topic of several research analyst reports. Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. HSBC raised shares of AbbVie from a “hold” rating to a “buy” rating and lifted their price target for the company from $225.00 to $265.00 in a research report on Wednesday, December 10th. JPMorgan Chase & Co. boosted their price objective on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Finally, DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target for the company. in a research report on Tuesday, November 4th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $248.11.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.